In the second of this three­-part series, Maarouf Hoteit, MD, summarizes the challenges of identifying the populations at risk for hepatitis C, reviews the surveillance recommendations of the American Association for the Study of Liver Diseases (AASLD) and the evidence that surveillance for HCC remains suboptimal in the United States.

Related Links

• Clinical Briefing: Enrolling Clinical Trials: Stereotactic Body Radiotherapy (SBRT) and Proton Therapy for Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma
• Case Study: A 46 y.o. man presents with a large hepatic mass involving the entire left lobe as well as portions of segment 8 with an additional 1.3 cm right hepatic tumor in segment 6, most likely multifocal HCC.
• Dr. Hoteit’s Profile